

December 20, 2024

<p>To <b>The Corporate Relations Department</b> <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p><b>Code: 540222</b></p>	<p>To <b>The Listing Department</b> <b>National Stock Exchange of India Ltd.,</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p><b>Code: LAURUSLABS</b></p>
---	---

**Sub: Update on investment in Laurus Bio Private Limited (Subsidiary Company) under Regulation 30(7) of SEBI (LODR) Regulations, 2015**

**Ref: Our letter dated December 06, 2024**

Dear Sir / madam,

With respect to above cited subject and reference and as per Regulation 30(7) of SEBI (LODR) Regulations, 2015, we would like to inform you that Eight Roads Ventures and F-Prime Capital (“Investors”) have together invested Rupees 120 Crores in Laurus Bio Private Limited, a subsidiary company of Laurus Labs Limited and the said transaction of the Investors was completed today i.e. on December 20, 2024.

Please take the above information on record.

Yours faithfully,

For **Laurus Labs Limited**

**G. Venkateswar Reddy**  
Company Secretary & Compliance Officer

**Registered Office**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anaparthi District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **E** info@lauruslabs.com  
**F** +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

**Corporate Office**

2<sup>nd</sup> Floor, SDE Serene Chambers, Road No. 7,  
Banjara Hills, Hyderabad - 500034, Telangana, India.

**T** +91 40 6659 4333, 3980 4333, 2342 0500 / 501,  
**F** +91 40 6659 4320 / 3980 4320